Wealthcare Advisory Partners LLC Grows Stock Holdings in The Clorox Company (NYSE:CLX)

Wealthcare Advisory Partners LLC lifted its position in shares of The Clorox Company (NYSE:CLXFree Report) by 22.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,590 shares of the company’s stock after purchasing an additional 291 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in Clorox were worth $258,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Prospera Private Wealth LLC purchased a new position in shares of Clorox during the 3rd quarter valued at approximately $27,000. Continuum Advisory LLC increased its position in Clorox by 300.0% in the third quarter. Continuum Advisory LLC now owns 184 shares of the company’s stock worth $30,000 after buying an additional 138 shares during the period. Quarry LP boosted its stake in Clorox by 99.1% during the 2nd quarter. Quarry LP now owns 229 shares of the company’s stock valued at $31,000 after purchasing an additional 114 shares during the period. Carolina Wealth Advisors LLC bought a new stake in Clorox during the 3rd quarter valued at $48,000. Finally, Friedenthal Financial bought a new stake in shares of Clorox during the third quarter valued at about $49,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Performance

NYSE:CLX opened at $160.03 on Wednesday. The firm has a market capitalization of $19.81 billion, a PE ratio of 55.76, a PEG ratio of 2.95 and a beta of 0.42. The Clorox Company has a 1 year low of $127.60 and a 1 year high of $171.37. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08. The firm’s fifty day simple moving average is $164.16 and its 200 day simple moving average is $156.91.

Clorox (NYSE:CLXGet Free Report) last released its earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.50. The business had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The firm’s revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the company earned $0.49 earnings per share. On average, sell-side analysts anticipate that The Clorox Company will post 6.87 EPS for the current year.

Clorox Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 29th will be given a dividend of $1.22 per share. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date is Wednesday, January 29th. Clorox’s dividend payout ratio (DPR) is currently 170.04%.

Analysts Set New Price Targets

CLX has been the topic of a number of research reports. Evercore ISI dropped their price objective on Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research note on Monday, October 14th. Jefferies Financial Group raised shares of Clorox from a “hold” rating to a “buy” rating and upped their price objective for the company from $174.00 to $187.00 in a research note on Tuesday, October 1st. JPMorgan Chase & Co. raised their target price on Clorox from $167.00 to $171.00 and gave the stock a “neutral” rating in a research report on Thursday, January 16th. StockNews.com cut shares of Clorox from a “buy” rating to a “hold” rating in a report on Sunday, January 5th. Finally, Barclays dropped their price objective on Clorox from $139.00 to $130.00 and set an “underweight” rating on the stock in a report on Friday, January 17th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $156.54.

Get Our Latest Research Report on Clorox

Clorox Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Further Reading

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLXFree Report).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.